Application of retinol X receptor alpha as target spot in preparation of medicine for treating sarcopenia
Through retinol X receptor α as a target, berthenin regulates the Mstn/Smad signaling pathway and inhibits Mstn expression, solving the problem of skeletal muscle reduction in sarcopenia treatment, providing new therapeutic intervention measures, and improving the elderly People’s quality of life and disease prognosis.
Patent Information
- Application Number
- CN202410957257.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Currently, there is a lack of effective drugs for the treatment of sarcopenia. The existing treatment mainly relies on nutritional support and exercise intervention. No methods can be found that can effectively regulate myostatin (Mstn) signaling pathways affect the quality of life and disease prognosis of the elderly.
Through retinol X receptor α (RXRα) as a target, berberine regulates the Mstn/Smad signaling pathway, inhibits the expression of Mstn, Smad3, and Smad4, increases the amount of skeletal muscle, and provides a new intervention target for the treatment of sarcopenia.
It was first discovered that RXRα is closely related to Mstn. Bernardine increases skeletal muscle mass by regulating the RXRα/Mstn/Smad axis, providing a theoretical basis for the treatment of sarcopenia and a new direction for drug development.
Smart Images

Figure HDA0004949222970000011 
Figure HDA0004949222970000021 
Figure HDA0004949222970000031
Abstract
Description
Technical Field
[0001] The present application relates to the field of biomedicine, and more specifically, to the use of retinol X receptor α as a target in the preparation of a drug for treating sarcopenia. Background Art
[0002] As people age, their muscles show a downward trend in terms of both content and strength. Human skeletal muscle mass reaches its peak around the age of 25-30, and by the age of 80, skeletal muscle mass has decreased by about 40-50%. As the largest non-fat component of the human body, skeletal muscle is the basis of all body movements. The reduction in skeletal muscle mass reduces the mobility of the elderly, is associated with frailty and disability, and increases the risk of fractures and falls. It also affects the development and prognosis of tumors and a variety of chronic diseases, seriously affecting the quality of life and disease prognosis of the elderly and increasing the risk of death. With the aggravation of population aging, the prevalence of sarcopenia has increased significantly, becoming a major health problem facing the current and future society.
[0003] Sarcopenia is an age-related disease and is also related to a variety of factors, such as insulin resistance and inflammatory response. However, the current treatment of sarcopenia mainly revolves around nutritional support and exercise intervention, and no effective drug for the treatment of sarcopenia has been found. Myostatin (Mstn) is an important skeletal muscle growth inhibitor in the body, which has a negative regulatory effect on skeletal muscle growth and plays an important role in the occurrence and development of sarcopenia. Mstn has typical characteristics of the transforming growth factor beta (TGFβ) superfamily. In addition to participating in the regulation of muscle growth, it is also closely related to glucose and lipid metabolism and insulin resistance, and participates in the development and metabolism of the body in many aspects. Inhibiting Mstn helps to increase skeletal muscle mass, and the transcription and activation of Mstn are regulated by a variety of factors, among which retinoid X receptor α (RXRα) plays a very important role in myoblast differentiation and skeletal muscle metabolism. If the Mstn-related signaling pathway can be downregulated by regulating RXRα, it will provide a new intervention target for the clinical treatment of sarcopenia. Summary of the invention
[0004] Berberine, also known as berberine, is a quaternary ammonium isoquinoline alkaloid extracted from plants such as Coptis chinensis, Phellodendron amurense and Ranunculaceae. It is widely used in clinical treatment of dysentery and bacterial gastroenteritis. Many studies have confirmed that berberine can improve glucose and lipid metabolism and reduce skeletal muscle insulin resistance. A few studies have shown that berberine can increase the number of skeletal muscle fibers. Our previous studies have confirmed that berberine can downregulate Mstn / Smad, increase skeletal muscle mass and improve body metabolism. However, it is still unclear what the specific targets of berberine on skeletal muscle are and how it regulates the Mstn and Smad pathways.
[0005] Based on the above research, the purpose of the present invention is to improve the mechanism of action of berberine in increasing skeletal muscle mass, provide a complete theoretical basis for the clinical treatment of sarcopenia with berberine, and explore specific intervention targets.
[0006] The transcription and activation of Mstn are regulated by many factors. In recent years, studies have shown that RXRα plays a very important role in myoblast differentiation and skeletal muscle metabolism, and may be related to the Mstn / Smad signaling pathway. Our research group first discovered through MEME-FIMO analysis that among the transcription factors related to Mstn expression, RXRα changed most significantly; using ChIP-seq technology, the results of IGV visualization analysis further showed that RXRα had a binding site that regulated the Mstn promoter. The above results confirmed the regulatory effect of RXRα on Mstn. Further cell experiments confirmed that in the skeletal muscle cell model of insulin resistance, the expression of RXRα and Mstn increased, and the expression of Smad3 and Smad4 in the downstream pathway of Mstn also increased, indicating that RXRα is closely related to the Mstn / Smad pathway and may be involved in the regulation of skeletal muscle mass. In summary, we first discovered that RXRα can regulate Mstn, and the RXRα / Mstn / Smad axis plays an important role in the process of berberine increasing skeletal muscle mass.
[0007] RXRα is closely related to the Mstn / Smad axis, and further studies are needed to confirm that berberine increases skeletal muscle mass by regulating RXRα and thereby affecting the Mstn / Smad axis.
[0008] In a first aspect, the present application discloses the use of retinol X receptor α as a target in the preparation of a drug for treating sarcopenia.
[0009] Furthermore, retinol X receptor α as a target means that berberine increases skeletal muscle mass by regulating the Mstn / Smad signaling pathway through retinol X receptor α.
[0010] Furthermore, the berberine regulates the Mstn / Smad signaling pathway by inhibiting the expression of retinol X receptor α.
[0011] Furthermore, regulating the Mstn / Smad signaling pathway refers to inhibiting the expression of Mstn, Smad3, and Smad4.
[0012] In a second aspect, the present application discloses the use of a substance that inhibits the expression of retinol X receptor α in the preparation of a drug for treating sarcopenia.
[0013] Furthermore, the substance that inhibits the expression of retinol X receptor α is berberine.
[0014] In a third aspect, the present application discloses a drug for treating sarcopenia, wherein the drug comprises a substance that inhibits the expression of retinol X receptor α.
[0015] Furthermore, the substance that inhibits the expression of retinol X receptor α is berberine.
[0016] In summary, this application has the following beneficial effects:
[0017] The present invention first discovered that the transcription factor RXRα is closely related to Mstn, and there is a clear targeted regulation on the Mstn promoter region. RXRα may be the target of berberine on skeletal muscle. Berberine increases muscle bone mass and treats sarcopenia by regulating the RXRα / Mstn / Smad signaling pathway. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 : RXRα is associated with Mstn;
[0019] ( Figure 1 -A: There are 68 transcription factors that can regulate Mstn. The intersection of 68 transcription factors and the difference results between HFD and NCD revealed that 12 transcription factors were related to the model. Figure 2 -B: There are 8 TFs that are upregulated in concert with Mstn, and RXRα is the most significantly changed transcription factor.
[0020] Figure 2 : IGV visualization display results diagram, RXRα has clear targeted regulation on Mstn;
[0021] Figure 3 : Berberine inhibits the expression of RXRα, Mstn, Smad3, and Smad4;
[0022] ( Figure 3 -A: PCR result graph; Figure 3 -B: Western blot results. )
[0023] Figure 4 :The results of cell immunofluorescence show that RXRα is involved in the process of berberine regulating Mstn / Smad. DETAILED DESCRIPTION
[0024] The technical scheme and effects of the present application are further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the invention, rather than to limit the invention.
[0025] Example 1: RXRα is associated with Mstn
[0026] The ChIP alas database was used to predict the transcription factors associated with Mstn expression using MEME-FIMO analysis. The results are shown in Figure 1 shown.
[0027] Depend on Figure 1 -A shows that there are 68 transcription factors that can regulate Mstn; the intersection of 68 transcription factors and the difference results of HFD vs NCD was used to find that 12 transcription factors were related to the model;
[0028] Depend on Figure 1 -B shows that by making a heat map of Mstn and differentially regulated transcription factors (TF), we found TFs with obvious differences, and discovered that there were 8 TFs that were consistently upregulated with Mstn. The heat map of the 8 transcription factors showed that RXRα was the transcription factor with the most significant change. After verification, RXRα was found for further research.
[0029] Example 2: RXRα has a clear targeted regulation on Mstn
[0030] ChIP-seq technology was used to visualize the expression of RXRα in the Mstn promoter region. Figure 2 shown.
[0031] Depend on Figure 2 It can be seen that RXRα was found to regulate the expression of Mstn, proving that RXRα has clear targeted regulation on the Mstn promoter region.
[0032] Example 3: Cell experiment-RXRα is involved in the process of berberine regulating Mstn / Smad
[0033] This cell experiment induced a C2C12 cell insulin resistance model by using a high-fat nutrient medium, and observed the results after berberine intervention.
[0034] First, the C2C12 skeletal muscle cells were thawed in a 100mm culture dish containing culture medium, cultured and passaged to restore the cells to their optimal vitality and state. They were divided into two groups, one as the control group and the other group added with high-fat nutrient medium to induce the construction of an insulin resistance cell model. The high-fat group was then treated with berberine at a concentration of 20umol / L for 24 hours. The expression of RXRα, Mstn, Smad3, Smad4, P13K, and AKt before and after the intervention was determined by Western blot and RT-PCR methods. The results are shown in Figure 2. Figure 3 As shown; and the fluorescence expression of RXRα and Mstn was detected by cell immunofluorescence laser confocal experiment. The results are as follows Figure 4 shown.
[0035] Statistical methods: The measurement data were expressed as mean ± SD, and one-way ANOVA was used for comparison between groups. Post Hoc Tests were used for pairwise comparison between groups, and Dunnett's T3 method was used for unequal variance. T test was used for comparison between two sample means, and SPSS21.0 statistical software was used for statistical analysis. P < 0.05 was considered to be statistically significant.
[0036] Depend on Figure 3 -A and B show that PCR ( Figure 3 -A) and Western blot( Figure 3 -B) The results showed that after insulin induction treatment of C2C12 skeletal muscle cells, RXRα, Mstn, Smad3 and Smad4 were increased at the same time. After berberine intervention, PCR and Western-blot results showed that the expression of RXRα, Mstn, Smad3 and Smad4 were downregulated.
[0037] Depend on Figure 4 It can be seen that the cell immunofluorescence results showed that the fluorescence expression of RXRα and Mstn in insulin-resistant skeletal muscle cells increased, and significantly decreased after berberine intervention, indicating that RXRα is involved in the process of berberine regulating Mstn / Smad.
[0038] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.
Claims
1. Application of retinol X receptor α as a target in the preparation of drugs for the treatment of sarcopenia.
2. The use according to claim 1, characterized in that: Retinol X receptor α as a target means that berberine increases skeletal muscle mass by regulating the Mstn / Smad signaling pathway through retinol X receptor α.
3. The use according to claim 2, characterized in that: The berberine regulates the Mstn / Smad signaling pathway by inhibiting the expression of retinol X receptor α.
4. The use according to claim 2 or 3, characterized in that: Regulating the Mstn / Smad signaling pathway refers to inhibiting the expression of Mstn, Smad3, and Smad4.
5. Use of a substance that inhibits the expression of retinol X receptor α in the preparation of a drug for treating sarcopenia.
6. The use according to claim 5, characterized in that: The substance that inhibits the expression of retinol X receptor α is berberine.
7. A drug for treating sarcopenia, characterized in that: The medicament includes a substance that inhibits the expression of retinol X receptor α.
8. The drug according to claim 7, characterized in that The substance that inhibits the expression of retinol X receptor α is berberine.
Citation Information
Patent Citations
Pharmaceutical composition and use thereof
CN115361945A
Application of berberine and derivatives thereof in preparation of skeletal muscle growth promoting products
CN116459249A
Myostatin and mimetics thereof
US20030140356A1
